VaxAlta is currently developing several glycoconjugate vaccines that target bacterial pathogens that impact animal health and human food safety (see our list of vaccines in the pipeline below).

VaxAlta also provides contract services to clients applying our proprietary platform technology toward the development of novel glycoconjugate vaccines against any pathogen (bacteria, virus, parasite, etc) where there is a unique glycan to target.

During our glycoconjugate vaccine workflow, VaxAlta also develops testing platforms for quality control that are available to our clients. This includes antibodies specific for the glycan antigen which can be used in diagnostic platforms.


Szymanski receives the Peter Gallagher Memorial Glycomics Award for Contributions to Health and Medical Research, October 8, 2018, at the Institute for Glycomics, Griffith University, Gold Coast, Australia.

VaxAlta presenting at the 2nd GlycoCom Meeting, October 3-6, 2018 in Dubrovnik, Croatia.

VaxAlta moves into a new incubation facility at the University of Alberta and continues to invest in livestock vaccine research through a new collaboration with the Faculty of Medicine to advance our next generation of livestock vaccines (October 1, 2018).

Szymanski completes successful 5-year term as the Alberta Innovates Tier 1 Strategic Chair in Bacterial Glycomics (2013-2018).

VaxAlta receives support from the Industrial Research Assistance Program (IRAP) in 2018.

A paper describing our second generation Campylobacter jejuni vaccine is published in Applied and Environmental Microbiology, September 2017.

Szymanski is President of the Canadian Society of Microbiologists in 2017.

VaxAlta participates in the Society for Glycobiology meeting in New Orleans, Louisiana, November 19-22, 2016.

Our Chief Financial Officer, Jason Ding, was selected as one of Edmonton's Top 40 Under 40, November 2016.

VaxAlta team members (Christine Szymanski and Harald Nothaft) receive the TEC Edmonton Patent Award on October 19, 2016.

A paper describing our first generation Campylobacter jejuni vaccine is published in Scientific Reports, May 2016.

VaxAlta receives support from the Industrial Research Assistance Program (IRAP) and the Alberta Livestock and Meat Agency (ALMA) in 2016.

Szymanski is President of the Society for Glycobiology in 2016.

VaxAlta receives the TEC Edmonton Spin-off Award on October 8, 2015.

Sept 24, 2015: Alberta livestock vaccine research gets a $660,000 booster

VaxAlta presenting at GlycoCom 2015 in Banff, Alberta on May 3-5, 2015

Glycoconjugate vaccine pipeline:

Campylobacter species

Campylobacter jejuni (poultry)

Campylobacter fetus venerealis (cattle) and C. fetus fetus (sheep)

Streptococcus species

Streptococcus suis (pigs)

Streptococcus uberis (cattle)

Clostridium perfringens (poultry)

Salmonella species (poultry)

Avian Pathogenic Escherichia coli (poultry)

Get In Touch With Us

Christine Szymanski, Ph.D.
CEO VaxAlta Inc.
Harald Nothaft, Ph.D.
CSO VaxAlta Inc.